IGKV2-18 as A Potential Drug Target (G28926)

Target Name: IGKV2-18

NCBI ID: G28926

Other Name(s): A29 | Immunoglobulin kappa variable 2-18 (pseudogene) | IGKV218 | immunoglobulin kappa variable 2-18 (pseudogene)

IGKV2-18 as A Potential Drug Target

IGKV2-18 (A29) is a non-coding RNA molecule that has been identified as a potential drug target (A29) and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made IGKV2 -18 an attractive target for researchers to study and develop new treatments.

IGKV2-18 is a short non-coding RNA molecule that consists of 29 amino acid residues. It is characterized by a specificity for the nuclear envelope, which is the thin layer of nuclear tissue that surrounds the nucleus of an organism. The nuclear envelope is Responsible for controlling the movement of substances into and out of the nucleus, and is involved in many important cellular processes, including the regulation of gene expression.

One of the unique features of IGKV2-18 is its ability to interact with various nuclear envelope proteins, which are involved in the regulation of nuclear envelope structure and function. This interaction between IGKV2-18 and these proteins makes it a promising target for drugs that can modulate the activity of these proteins and disrupt their functions.

IGKV2-18 has been shown to play a role in the regulation of various cellular processes, including cell growth, apoptosis (programmed cell death), and transcriptional regulation. For example, studies have shown that IGKV2-18 can interact with the protein p180 and promote its phosphorylation, which is associated with cell growth and survival. Additionally, IGKV2-18 has been shown to play a role in the regulation of apoptosis, which is the process by which cells decide when to die and are programmed to do so.

In addition to its role in apoptosis, IGKV2-18 has also been shown to be involved in the regulation of transcriptional activity. Studies have shown that IGKV2-18 can interact with the protein SkrP, which is involved in the negative regulation of gene expression. This interaction between IGKV2-18 and SkrP suggests that IGKV2-18 may be a useful biomarker for assessing the activity of drugs that target gene expression.

IGKV2-18's unique structure and function have made it an attractive target for drugs that can modulate the activity of nuclear envelope proteins and disrupt their functions. Studies have shown that IGKV2-18 can be modulated by various small molecules, including inhibitors of protein synthesis, such as rapamycin, and drugs that target the activity of nuclear envelope proteins, such as rapamycin and aspirin. In addition, IGKV2-18 can also be used as an indicator to study cell death and cell cycle and is a promising drug target.

Protein Name: Immunoglobulin Kappa Variable 2-18 (pseudogene)

More Common Targets